Brand Name | Status | Last Update |
---|---|---|
animi-3 | unapproved drug other | 2013-02-06 |
animi-3 with vitamin d | unapproved drug other | 2011-05-23 |
bp vit 3 | unapproved drug other | 2025-02-13 |
c-nate dha | unapproved drug other | 2024-01-22 |
citranatal assure | unapproved drug other | 2024-01-08 |
citranatal dha | unapproved drug other | 2020-07-28 |
citranatal essence | unapproved drug other | 2020-07-07 |
citranatal harmony | unapproved drug other | 2012-01-18 |
citranatal harmony 2.1 | unapproved drug other | 2019-05-14 |
citranatal harmony 3.0 | unapproved drug other | 2025-05-19 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 1 | 3 | — | — | — | 4 |
Lung neoplasms | D008175 | — | C34.90 | — | 3 | — | — | — | 3 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 3 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 3 | — | — | — | 3 |
Lymphoid leukemia | D007945 | — | C91 | 1 | 3 | — | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
Follicular lymphoma | D008224 | — | C82 | 1 | 1 | — | — | — | 2 |
Leukemia | D007938 | — | C95 | 1 | 2 | — | — | — | 2 |
Esophageal neoplasms | D004938 | — | C15 | — | 2 | — | — | — | 2 |
B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | — | 1 |
Drug common name | Doconexent |
INN | doconexent |
Description | All-cis-docosa-4,7,10,13,16,19-hexaenoic acid is a docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19. It has a role as a nutraceutical, an antineoplastic agent, a human metabolite, a Daphnia tenebrosa metabolite, a mouse metabolite and an algal metabolite. It is a docosahexaenoic acid and an omega-3 fatty acid. It is a conjugate acid of a (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O |
PDB | — |
CAS-ID | 6217-54-5 |
RxCUI | — |
ChEMBL ID | CHEMBL367149 |
ChEBI ID | 28125 |
PubChem CID | 445580 |
DrugBank | DB03756 |
UNII ID | ZAD9OKH9JC (ChemIDplus, GSRS) |